According to a study, Ozempic can be made for less than $5 a month

Novo Nordisk's Ozempic could be manufactured for an estimated 89 cents to $4.73 for a month's supply. Researchers found the drug can be made for less than $5 a month, study suggests. The study includes a profit margin of about $4 per month.

Novo Nordisk to acquire Cardior Pharmaceuticals and strengthen pipeline in cardiovascular disease. Cardior is a leader in the discovery and development of therapies that target RNA as a means to prevent, repair and reverse diseases of the heart. The company’s therapeutic approach targets distinctive non-coding RNAs as a platform for addressing root causes of cardiac dysfunctions.

Novo Nordisk's Ozempic slashed the risk of kidney disease progression in trial. The results add to the growing evidence that the highly popular injection has broader health benefits for patients beyond treating Type 2 diabetes. The trial adds to the evidence growing that the drug has broad health benefits beyond treating diabetes.